<DOC>
	<DOCNO>NCT01341106</DOCNO>
	<brief_summary>This study examine whether 12 month treatment entecavir ( Baraclude® ) effect change liver stiffness measurement ( LSM ) hyaluronan measurement patient chronic hepatitis B infection .</brief_summary>
	<brief_title>Induction Fibrosis Regression Patients With Chronic Hepatitis B Infection</brief_title>
	<detailed_description>Patients chronic hepatitis B infection relevant liver fibrosis treat entecavir 5 year anti-HBs seroconversion 6-12 month anti-HBe seroconversion HBeAg loss . There 9 visit treatment patient . At visit , patient consent give 20 ml blood sample study examination 40 ml blood sample research purpose .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>chronic hepatitis B infection detectable HBV ( hepatitis B virus ) DNA baseline result current liver biopsy ( date liver biopsy must longer 3 month date screen visit ) detection relevant liver fibrosis liver histology percutaneous laparoscopic biopsy ( histologically ≥ F2 ) estimation experience pathologist liver pathology sufficient evaluability biopsy ( usually evaluation portal least 8 field ) Therapy indication accord current guideline cHBV infection ( virus replication presence liver cirrhosis , detection HBVDNA ≥ 2000 IU / ml and/or liver histology inflammatory Grade ≥2 / fibrosis stage 2 presence ALT &lt; 5 x ULN ) nonpregnant nonbreastfeeding woman , fitful one follow criterion : * postmenopausal ( 12 month natural amenorrhea 6 month amenorrhea serum FSH ( follicle stimulate hormone ) &gt; 40mlU/ml ) 6 week surgical sterilization bilateral tubal transection bilateral oophorectomy without hysterectomy Correct application two method sure contraception ( combination hormonal contraceptive ( pill , hormone IUD ( intrauterine device ) , DepoProvera , Implanon , contraceptive patch vaginal ring ) IUD barrier contraceptive spermicide ( diaphragm , cervical cap , LEA contraceptive , female condom condom ) spermicide . Sexual abstinence 2 week first administration study medication , study period study 30 day ( time elimination study medication ) Patients , female sexual partner Male partner female patient , study inclusion , sterile one sexual partner female patient Patients willing able complete requirement study anamnestic know hypersensitivity Baraclude® ingredient drug similar chemical structure Participation patient another clinical study within last 4 week prior inclusion simultaneous participation another clinical study anamnestic know substance dependance another disease , allow person understand essence importance possible consequence trial lack cooperation inform consent coinfection hepatitis C , hepatitis D HIV detection hepatocellular carcinoma serious , chronic disease estimate prognosis survival shorter study period 5 year every previous therapy lamivudine telbivudine previous therapy antiviral substance within last 6 month study inclusion contraindication use entecavir creatinine clearance &lt; 50 ml / min / need hemodialysis MELD score &gt; 15 point / detection ascites</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>chronic hepatitis B</keyword>
	<keyword>liver fibrosis</keyword>
	<keyword>treatment Entecavir</keyword>
</DOC>